Dyslipidemias

• 

  Subject Areas on Research

  • A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. 
  • A Cost Analysis of Universal versus Targeted Cholesterol Screening in Pediatrics. 
  • A review of cardiovascular risk factors in US military personnel. 
  • A sex-specific relationship between capillary density and anaerobic threshold. 
  • Aerobic and resistance training effects on energy intake: the STRRIDE-AT/RT study. 
  • Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. 
  • Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. 
  • An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment: Lessons From the PALM Study (Patient and Provider Assessment of Lipid Management). 
  • Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. 
  • Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. 
  • Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. 
  • Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. 
  • Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. 
  • Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. 
  • Behavioral health mediators of the link between posttraumatic stress disorder and dyslipidemia. 
  • Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Beverage Consumption and Longitudinal Changes in Lipoprotein Concentrations and Incident Dyslipidemia in US Adults: The Framingham Heart Study. 
  • Branched-chain amino acids in disease. 
  • Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. 
  • Cardiovascular complications of diabetic kidney disease. 
  • Cardiovascular health knowledge and preventive practices in people living with HIV in Kenya. 
  • Care continuity impacts medicare expenditures of older adults: Fact or fiction? 
  • Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. 
  • Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. 
  • Communicating health information and improving coordination with primary care (CHIIP): Rationale and design of a randomized cardiovascular health promotion trial for adult survivors of childhood cancer. 
  • Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations. 
  • Cross-sectional relations of lipid concentrations to left ventricular structural attributes. 
  • Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. 
  • Dietary carbohydrate intake and high-sensitivity C-reactive protein in at-risk women and men. 
  • Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers. 
  • Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia. 
  • Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. 
  • Effect of exercise intensity and volume on persistence of insulin sensitivity during training cessation. 
  • Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer. 
  • Ethnic variation in the impact of metabolic syndrome components and chronic kidney disease. 
  • Fibrate use in the United States and Canada. 
  • Frequency of Disparities in Laboratory Testing After Statin Initiation in Subjects ≥65 Years. 
  • Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. 
  • Greater weight loss with increasing age in the weight loss maintenance trial. 
  • Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. 
  • Impact of 5-year weight change on blood pressure: results from the Weight Loss Maintenance trial. 
  • Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. 
  • Impact of metabolic syndrome on perioperative complication rates after total joint arthroplasty surgery. 
  • Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. 
  • In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG. 
  • Inactivity, exercise, and visceral fat. STRRIDE: a randomized, controlled study of exercise intensity and amount. 
  • Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation. 
  • Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals. 
  • Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. 
  • Lifetime risk for developing dyslipidemia: the Framingham Offspring Study. 
  • Lipid Testing and Statin Dosing After Acute Myocardial Infarction. 
  • Lipid profiles of pediatric hematopoietic stem cell transplant survivors. 
  • Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination? 
  • Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). 
  • Lipids and diabetic retinopathy. 
  • Lipids in high-risk patients presenting with ischemic stroke or transient ischemic attack: are we missing the target? 
  • Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. 
  • Low-density lipoprotein cholesterol level and statin use among Medicare beneficiaries with diabetes mellitus. 
  • Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. 
  • Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. 
  • Medication Discontinuation in the IMPROVE-IT Trial. 
  • Metabolic syndrome and risk of age-related macular degeneration. 
  • Metabolic syndrome components and age-related cataract: the Singapore Malay eye study. 
  • MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection. 
  • Niacin and heart disease prevention: Engraving its tombstone is a mistake. 
  • Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. 
  • PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. 
  • Patient perspectives on having multiple versus single prescribers of chronic disease medications: results of a qualitative study in a veteran population. 
  • Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. 
  • Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. 
  • Prescriber Continuity and Disease Control of Older Adults. 
  • Prescriber continuity and medication adherence for complex patients. 
  • Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. 
  • Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. 
  • Prevention of future cardiovascular disease in high-risk pediatric patients: a role for lipid lowering therapy? 
  • Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. 
  • Reduced Impact of Obesity on Short-Term Surgical Outcomes, Patient-Reported Pain Scores, and 30-Day Readmission Rates After Complex Spinal Fusion (≥7 Levels) for Adult Deformity Correction. 
  • Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. 
  • Relationships between exercise-induced reductions in thigh intermuscular adipose tissue, changes in lipoprotein particle size, and visceral adiposity. 
  • Retinal vascular caliber, blood pressure, and cardiovascular risk factors in an Asian population: the Singapore Malay Eye Study. 
  • Retinal vascular manifestations of metabolic disorders. 
  • Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. 
  • Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. 
  • Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. 
  • Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. 
  • Sex Differences in the Use of Statins in Community Practice. 
  • Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. 
  • Statins in adult patients with HIV: Protocol for a systematic review and network meta-analysis. 
  • Study protocol: Couples Partnering for Lipid Enhancing Strategies (CouPLES) - a randomized, controlled trial. 
  • The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study. 
  • The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids. 
  • The effects of aerobic, resistance, and combination training on insulin sensitivity and secretion in overweight adults from STRRIDE AT/RT: a randomized trial. 
  • The relationship between the blood pressure responses to exercise following training and detraining periods. 
  • Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation. 
  • Weight and Metabolic Outcomes 12 Years after Gastric Bypass. 
  • What Defines a Valuable Investment in Global Health Research? 
• 

  Keywords of People

  • Yancy Jr., William Samuel, Associate Professor of Medicine, Medicine, General Internal Medicine